Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + carboplatin + enoxaparin
- Development stage
- Unknown
- Lead developer
- Mashhad University of Medical Sciences
- Modality
- Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
This investigational chemotherapeutic combination regimen, developed by Mashhad University of Medical Sciences, is being evaluated for the neoadjuvant treatment of non-metastatic esophageal squamous cell carcinoma. The regimen consists of standard neoadjuvant chemoradiotherapy using paclitaxel and carboplatin, supplemented with daily subcutaneous enoxaparin. Paclitaxel is a taxane that acts as a microtubule-stabilizing agent, interfering with the G2/M phase of the cell cycle to inhibit mitosis. Carboplatin is a platinum-based antineoplastic agent that induces DNA cross-linking, thereby inhibiting DNA synthesis and cell replication. Enoxaparin, a low molecular weight heparin (LMWH), is added to the regimen to investigate whether its anticoagulant and potential anti-tumor properties can improve clinical and pathological response rates in patients undergoing concurrent radiotherapy.
- Other names
- Enoxaparin with Neoadjuvant ChemoradiationChemotherapeutic Combinations-Mashhad University of Medical Sciences-esophageal squamous cell carcinoma
02
Targets
ATIII (Antithrombin III)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on paclitaxel + carboplatin + enoxaparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + carboplatin + enoxaparin.